Becton, Dickinson and Company BDX BioPharma Systems — D&A

Other segment segments

Similar metrics at other companies

PFEBiopharma — D&A

$348M+5.1%

AVT

AVTRBioscience & Medtech Products — D&A

$49.2M+12.3%

OPKPharmaceutical — D&A

$18.26M+2.7%

CAHPharmaceutical and Specialty Solutions — D&A

$70M+59.1%

AMP

AMPHPharmaceutical Products — D&A

$14.35M+5.4%

ATRPharma — D&A

$35.64M+14.4%

Questions, answered.

What is Becton, Dickinson and Company's biopharma systems — D&A?

Becton, Dickinson and Company (BDX) reported biopharma systems — D&A of $27M in Q1 2026.

What does biopharma systems — D&A mean?

This metric reflects the non-cash expense allocated to the BioPharma Systems segment for the wear and tear of physical assets and the amortization of intangible assets over their useful lives. It provides insight into the capital intensity of the segment's manufacturing operations and the historical investment in technology or intellectual property. Monitoring this helps investors understand the segment's ongoing capital expenditure requirements and the impact of past acquisitions on current earnings.